U.S. Multimodality Diagnostic Imaging Systems Market: $4.86B

Market Outlook

By 2035, the U.S. Multimodality Diagnostic Imaging Systems Market is expected to reach approximately USD 4.86 billion, expanding at a CAGR of 8.65% during the forecast period from 2026 to 2035. The market was valued at an estimated USD 2.12 billion in 2025. Historical analysis covers 2021 to 2024, and all market values are expressed in USD billions.

For the purpose of this report, multimodality diagnostic imaging systems include integrated and digitally connected platforms that combine anatomical, functional, molecular, physiological, or quantitative imaging information. The market principally covers PET/CT, SPECT/CT, PET/MRI, multimodality image-fusion platforms, hybrid ultrasound-guided imaging environments, and integrated systems that combine data from CT, MRI, nuclear medicine, angiography, ultrasound, and other compatible imaging sources. The market estimate includes new equipment sales, major hardware upgrades, directly associated software, advanced reconstruction and fusion applications, and service-linked platform revenue. It excludes radiopharmaceutical sales, stand-alone single-modality scanners, and routine imaging interpretation fees.

The U.S. market is moving from conventional image acquisition toward integrated diagnostic decision environments. Hospitals no longer evaluate hybrid scanners solely according to resolution, detector performance, magnet strength, slice count, or purchase price. Procurement decisions increasingly consider patient throughput, radiotracer efficiency, repeat-scan reduction, protocol consistency, interoperability, staffing requirements, uptime, total ownership cost, and the system’s ability to support several clinical service lines from one capital asset.

Clinical demand is supported by the scale of cancer, cardiovascular disease, neurological disorders, musculoskeletal conditions, and age-related chronic illness in the United States. More than 1.8 million new cancer cases are reported annually in the country, while over seven million Americans aged 65 and older are living with Alzheimer’s dementia. These conditions frequently require longitudinal imaging across multiple modalities for lesion characterization, staging, treatment planning, therapy-response assessment, disease-progression monitoring, and recurrence detection.

Multimodality imaging is especially valuable when one imaging method cannot provide sufficient diagnostic information independently. CT offers rapid anatomical localization, MRI provides superior soft-tissue characterization, PET identifies metabolic and molecular activity, SPECT measures physiological function, and ultrasound delivers real-time imaging without ionizing radiation. Combining these datasets can reduce uncertainty, improve anatomical correlation, support more targeted intervention, and help clinicians evaluate both disease structure and biological activity.

The historical market expanded from approximately USD 1.54 billion in 2021 to USD 1.94 billion in 2024. Growth during this period was supported by the recovery of elective imaging volumes, hospital replacement of aging nuclear medicine infrastructure, increased oncology imaging demand, greater use of prostate-specific membrane antigen PET, expansion of cardiac imaging, and investment in AI-assisted reconstruction and enterprise image-management platforms. The market reached USD 2.12 billion in 2025 as health systems accelerated PET/CT modernization, adopted higher-sensitivity detector platforms, expanded theranostics programs, and integrated multimodality analysis into oncology, neurology, and cardiology workflows.

From 2026 through 2035, value growth will increasingly come from digital PET/CT, long-axial-field-of-view imaging, total-body systems, quantitative SPECT/CT, PET/MRI, spectral and photon-counting data integration, AI-supported fusion, automated lesion tracking, and software platforms that normalize studies acquired across different devices and facilities. The most commercially successful systems will be those that deliver not only better images, but also measurable gains in departmental productivity, diagnostic confidence, patient access, and care-pathway economics.

Introduction

According to the U.S. Multimodality Diagnostic Imaging Systems Market Report, the industry occupies a high-value position between conventional radiology, nuclear medicine, precision oncology, cardiology, neurology, image-guided intervention, and digital diagnostic workflow. The market is smaller than the total U.S. diagnostic imaging equipment market, but it represents one of its most technologically sophisticated and strategically important categories.

The United States provides a strong operating environment for multimodality imaging because it combines a large hospital base, mature specialist networks, substantial oncology infrastructure, advanced academic research institutions, established nuclear medicine capabilities, and comparatively high adoption of premium medical technology. The country has approximately 6,100 hospitals, more than 907,000 staffed hospital beds, and over 35 million annual hospital admissions. It also has an extensive network of freestanding imaging centers, radiation oncology facilities, cancer institutes, cardiology centers, neurological centers, and outpatient specialty providers.

The U.S. market is not limited to the physical integration of two scanners. It increasingly includes the digital integration of images, biomarkers, radiotracer data, anatomical segmentation, prior studies, treatment plans, pathology information, and longitudinal clinical records. A PET/CT platform may therefore compete not only on detector sensitivity and CT performance, but also on automated patient positioning, attenuation correction, dose optimization, lesion quantification, response assessment, reporting integration, and the ability to connect diagnostic imaging with radiopharmaceutical therapy.

The economics of multimodality imaging are also different from those of routine imaging equipment. A conventional capital purchase may be justified primarily by replacement need and scan volume. A multimodality platform is more often evaluated as a service-line investment. Hospital executives examine whether the asset can increase referrals, retain complex patients, support oncology accreditation, strengthen a theranostics program, improve cardiac or neurological differentiation, attract specialists, and reduce the need to send advanced cases to competing institutions.

Capital requirements remain substantial. Depending on system type, configuration, construction requirements, shielding, service agreement, detector architecture, software package, and facility readiness, installed project costs may range from several million dollars to considerably higher levels for advanced research-grade or total-body platforms. Site planning may require room renovation, power infrastructure, cooling, radiation protection, radiopharmacy access, MRI safety controls, and specialized clinical staffing. Consequently, procurement cycles can extend across several budget years and typically involve radiology leadership, nuclear medicine physicians, medical physicists, finance departments, facilities teams, information technology departments, and value-analysis committees.

The market is nevertheless becoming more accessible. Smaller-footprint PET/CT systems, air-cooled designs, modular detector configurations, lower-helium MRI platforms, mobile imaging models, cloud-based post-processing, and enterprise software licenses are reducing some of the barriers faced by community hospitals and outpatient centers. Software-enabled fusion also allows providers to extract greater clinical value from existing scanners without immediately replacing every imaging asset.

An important strategic shift is the movement from modality ownership to pathway ownership. Leading manufacturers are connecting acquisition systems with reconstruction software, image management, advanced visualization, analytics, service, radiopharmaceutical workflows, and treatment-response applications. This enables vendors to build longer-term relationships with health systems and creates higher switching costs than a stand-alone hardware sale.

The U.S. market will therefore be shaped by two simultaneous procurement patterns through 2035. Major academic and referral institutions will invest in high-sensitivity, total-body, quantitative, and research-capable systems. Community hospitals and outpatient providers will seek scalable platforms with reliable throughput, predictable maintenance expense, simplified protocols, and access to advanced software without excessive operational complexity.

Key Market Drivers: What’s Fueling the U.S. Multimodality Diagnostic Imaging Systems Market Boom?

The first major driver is the country’s sustained oncology burden. The United States reports more than 1.8 million new cancer cases annually and over 600,000 cancer deaths. Cancer patients often require multiple imaging examinations across diagnosis, staging, radiation planning, surgery, systemic treatment, surveillance, and recurrence evaluation. Multimodality systems are particularly important in lung cancer, lymphoma, breast cancer, prostate cancer, colorectal cancer, head and neck cancer, melanoma, and neuroendocrine tumors.

PET/CT remains central to oncology because it combines metabolic activity with anatomical localization. Expanding use of targeted radiotracers is increasing the clinical value of these systems beyond conventional fluorodeoxyglucose imaging. PSMA PET has strengthened prostate cancer staging and recurrence assessment, while somatostatin-receptor imaging supports neuroendocrine tumor management. As radiopharmaceutical therapy programs expand, diagnostic and post-treatment imaging will become more closely connected with patient selection, dosimetry, treatment planning, and therapy-response monitoring.

A second driver is the growth of precision medicine and theranostics. U.S. cancer centers are building programs that pair diagnostic molecular imaging with targeted radiopharmaceutical treatment. This model creates demand for PET/CT, quantitative SPECT/CT, dosimetry software, automated segmentation, serial-image comparison, and integrated treatment documentation. Multimodality systems become part of a recurring care pathway rather than a one-time diagnostic transaction.

A third driver is the neurological disease burden. Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, brain tumors, traumatic brain injury, and cerebrovascular disease create demand for structural, functional, metabolic, and perfusion imaging. MRI remains the principal anatomical platform for many neurological indications, while PET can identify molecular or metabolic changes that may not be visible on structural imaging alone. PET/MRI, PET/CT, EEG-MRI integration, functional MRI, and advanced image-fusion software are therefore gaining strategic importance in major neurological centers.

The introduction and expansion of disease-modifying therapies for Alzheimer’s disease are also changing imaging requirements. Eligible patients may require amyloid confirmation, baseline MRI, follow-up MRI, and repeated assessment for treatment-related imaging abnormalities. This increases the importance of coordinated imaging pathways, standardized protocols, longitudinal comparison, and software capable of combining structural and molecular information.

A fourth driver is growth in cardiovascular imaging. Cardiac PET, SPECT/CT, coronary CT angiography, cardiac MRI, echocardiography, and multimodality structural-heart planning are being used to evaluate coronary artery disease, myocardial perfusion, viability, inflammation, infiltrative disease, congenital abnormalities, cardiomyopathy, and valve disorders. Health systems are building integrated cardiovascular imaging programs in which different modalities are selected according to patient risk, clinical question, renal function, rhythm, body habitus, implanted devices, and prior results.

A fifth driver is hospital capital replacement. A meaningful portion of the U.S. imaging installed base is operating beyond the preferred replacement cycle. Older systems may have lower detector sensitivity, slower reconstruction, limited software compatibility, higher service costs, reduced radiotracer efficiency, and weaker support for modern quantitative protocols. Replacement decisions are being accelerated where aging equipment limits throughput, creates downtime, or prevents participation in advanced oncology and neurology programs.

A sixth driver is pressure to improve radiology productivity. The United States faces persistent radiologist, nuclear medicine physician, technologist, nursing, and medical physicist capacity constraints. Imaging demand is rising faster than the availability of experienced staff in many markets. Manufacturers are responding with automated positioning, protocol selection, image registration, organ segmentation, lesion measurement, motion correction, reconstruction, quality control, and report preparation.

These capabilities are increasingly important to procurement committees. A premium system can be economically justified when it allows a department to scan more patients, shorten appointment times, reduce manual processing, lower repeat-examination rates, or make complex protocols less dependent on a small number of highly experienced operators.

A seventh driver is outpatient imaging migration. Freestanding imaging centers and ambulatory specialty providers are expanding their role in MRI, CT, PET/CT, cardiac imaging, cancer surveillance, and preventive diagnostic services. These operators require high equipment utilization and predictable scheduling to support their economics. They are receptive to systems that combine a smaller footprint, simplified installation, remote service, automated workflow, broad clinical utility, and lower total ownership cost.

An eighth driver is radiotracer and detector innovation. Higher-sensitivity detectors, digital photon detection, improved time-of-flight performance, longer axial fields of view, advanced collimation, and lower-noise reconstruction allow systems to generate clinically useful studies with shorter acquisition times or lower administered activity. This can increase throughput, improve patient tolerance, expand pediatric and research applications, and reduce dependence on high radiotracer doses.

A ninth driver is enterprise imaging integration. Large U.S. health systems frequently operate scanners from several manufacturers across hospitals, outpatient centers, oncology clinics, and acquired physician practices. They need platforms capable of managing heterogeneous DICOM data, prior examinations, cloud-based viewing, multimodality fusion, structured reporting, and longitudinal lesion tracking. Interoperability has consequently become a core purchasing criterion rather than an optional information-technology feature.

A tenth driver is reimbursement-supported clinical adoption. Medicare and commercial insurers cover a wide range of CT, MRI, PET, SPECT, and ultrasound examinations when applicable medical-necessity requirements are met. Reimbursement does not eliminate financial pressure, but it creates established payment pathways for many high-value applications. Systems that support documentation, appropriate-use criteria, quantitative reporting, and efficient coding can strengthen the financial case for adoption.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. Multimodality Diagnostic Imaging Systems Market is increasingly focused on sensitivity, quantification, automation, cross-modality consistency, and patient-centered workflow. The competitive question is no longer simply which system produces the sharpest image. Buyers want to know whether a platform can produce reproducible information across time, scanners, locations, radiotracers, and treatment cycles.

Digital PET/CT is one of the most important innovation areas. Silicon photomultiplier detectors and improved time-of-flight performance can strengthen lesion detectability, quantitative accuracy, and acquisition efficiency. Higher sensitivity may allow shorter scans or lower administered activity, which can improve patient experience and increase daily capacity. These benefits are commercially important in high-volume oncology programs and in facilities where radiotracer supply is constrained.

Long-axial-field-of-view and total-body PET/CT represent a higher-end innovation cycle. These platforms can image a larger portion of the body simultaneously and generate dynamic information across multiple organs. They support research in systemic disease, pharmacokinetics, immunology, oncology, infection, inflammation, and treatment response. Their near-term adoption will remain concentrated in academic medical centers and major referral institutions because of capital requirements, data intensity, and specialized research needs. Over time, design modularity and workflow improvements may broaden adoption.

Quantitative SPECT/CT is also advancing. Modern systems combine improved detector technology, reconstruction algorithms, attenuation correction, localization, and dosimetry applications. SPECT/CT is particularly important because it supports widely used and comparatively accessible nuclear medicine procedures while also playing a growing role in post-therapy imaging. In many community hospitals, SPECT/CT offers a more practical entry point into multimodality imaging than PET/MRI or total-body PET/CT.

PET/MRI is evolving through faster MRI sequences, improved attenuation correction, motion management, organ-specific coils, pediatric protocols, and more integrated reconstruction. The technology provides strong soft-tissue contrast and reduced CT-related radiation exposure, making it attractive for selected brain, pelvic, liver, pediatric, and research applications. Adoption remains limited by capital cost, examination duration, operational complexity, and the need for personnel trained in both MRI and nuclear medicine. Its commercial opportunity is therefore concentrated in high-acuity centers rather than routine community imaging.

AI-assisted multimodality analysis is becoming a strategic layer across the market. Algorithms are being used to register studies, detect lesions, segment organs, calculate metabolic tumor volume, compare serial examinations, quantify brain structures, prioritize worklists, and prepare structured findings. The strongest solutions will be those that operate reliably across equipment brands and clinical environments rather than performing well only on data from a single scanner.

Spectral and photon-counting CT are expanding the amount of diagnostic information that can be extracted from CT acquisition. Material decomposition, virtual non-contrast imaging, iodine mapping, improved spatial resolution, and reduced artifact may provide additional information for oncology, cardiovascular imaging, and treatment planning. When spectral CT data are combined with PET, MRI, ultrasound, or prior examinations, they can create a richer multimodality dataset without necessarily adding a separate patient visit.

Image fusion is also moving closer to intervention. MRI-ultrasound fusion supports targeted prostate biopsy and selected liver or musculoskeletal procedures. CT, MRI, PET, and ultrasound data can be combined for surgical planning, radiation oncology, ablation, and navigation. This expands the market beyond diagnostic interpretation into procedure guidance and treatment delivery.

Manufacturers are also improving system economics through predictive maintenance, remote monitoring, component modularity, energy efficiency, lower helium dependence, cloud-based software deployment, and upgradeable detector architectures. U.S. providers are placing greater value on systems that can remain clinically current through software and hardware upgrades rather than requiring complete replacement whenever reconstruction or workflow technology advances.

Segmentation Insights

The U.S. Multimodality Diagnostic Imaging Systems Market is segmented on the basis of system type, clinical application, technology and configuration, end user, and region.

By System Type

PET/CT Systems

PET/CT systems represent the largest system-type segment and accounted for an estimated USD 1.03 billion in U.S. market revenue in 2025. The category includes conventional PET/CT, digital PET/CT, extended-field-of-view systems, total-body platforms, mobile configurations, and directly associated reconstruction and analysis software.

Demand is led by oncology, but neurology, cardiology, infection imaging, inflammation assessment, and theranostics are becoming more important. PET/CT has a strong installed-base advantage, broad physician familiarity, and established clinical pathways. Future value growth will be driven by digital detector upgrades, higher sensitivity, reduced scan time, lower-dose protocols, advanced radiotracers, and quantitative treatment-response applications.

SPECT/CT Systems

SPECT/CT systems generated an estimated USD 0.45 billion in 2025. The segment includes general-purpose hybrid systems, cardiac-focused configurations, quantitative SPECT platforms, solid-state detector systems, and associated processing applications.

SPECT/CT remains important because it supports bone imaging, myocardial perfusion, infection localization, parathyroid imaging, endocrine applications, sentinel-node assessment, renal imaging, and post-therapy dosimetry. The systems are used across academic centers, community hospitals, cardiology practices, and nuclear medicine departments. Growth will be supported by detector modernization, quantitative imaging, cardiac workflow, and radiopharmaceutical therapy follow-up.

PET/MRI Systems

PET/MRI accounted for approximately USD 0.19 billion in 2025. Although smaller by installed base, it is expected to record one of the fastest growth rates through 2035. The technology combines molecular imaging with high soft-tissue contrast and can reduce exposure to CT-related ionizing radiation.

Principal applications include brain imaging, epilepsy, neurodegenerative disease, pediatric oncology, pelvic cancer, prostate cancer, liver disease, and clinical research. Commercial expansion will depend on faster protocols, better attenuation correction, improved reimbursement economics, stronger clinical evidence, and greater operational standardization.

Multimodality Image-Fusion and Analysis Platforms

Multimodality fusion and analysis platforms represented an estimated USD 0.28 billion in 2025. This category includes software that combines CT, MRI, PET, SPECT, ultrasound, angiography, pathology-related images, treatment-planning data, and longitudinal examinations.

These platforms allow providers to obtain greater value from existing equipment and are increasingly procured at the enterprise level. Growth is being supported by cloud deployment, vendor-neutral architecture, oncology lesion tracking, brain quantification, radiation planning, theranostics dosimetry, surgical navigation, and AI-assisted interpretation.

Other Integrated Hybrid Imaging Systems

Other integrated systems accounted for approximately USD 0.17 billion in 2025. This category includes MRI-ultrasound fusion, CT-angiography integration, ultrasound-navigation platforms, multimodality neuroimaging systems, and specialized imaging configurations used in image-guided procedures.

Demand is more fragmented than in PET/CT or SPECT/CT but can be clinically significant. MRI-ultrasound fusion is gaining adoption in targeted prostate biopsy, while integrated CT, angiography, and ultrasound data support cardiovascular, hepatic, vascular, and interventional planning. These systems often compete on workflow specialization rather than broad radiology utilization.

By Clinical Application

Oncology

Oncology is the dominant clinical application and represented approximately 52% of the U.S. market in 2025. Multimodality imaging supports cancer detection, staging, biopsy planning, radiation planning, surgical assessment, treatment selection, response evaluation, and surveillance.

PET/CT is the primary hybrid platform, but MRI, SPECT/CT, ultrasound fusion, spectral CT, and advanced visualization also contribute. Demand is strongest in lung, prostate, breast, colorectal, lymphoma, melanoma, head and neck, neuroendocrine, and gynecologic cancer pathways. Oncology will remain the largest application through 2035 because of cancer incidence, therapeutic complexity, targeted radiotracer expansion, and rising demand for quantitative treatment monitoring.

Neurology

Neurology is a high-growth application segment covering Alzheimer’s disease, Parkinson’s disease, epilepsy, brain tumors, multiple sclerosis, stroke, traumatic brain injury, and neuropsychiatric research.

PET/MRI and PET/CT can combine molecular or metabolic information with structural anatomy. MRI-based volumetric analysis, amyloid and tau imaging, perfusion studies, functional MRI, and EEG-MRI fusion are creating more data-intensive neurological workflows. The segment will benefit from the need to identify eligible patients for new therapies and monitor neurological treatment safety.

Cardiology

Cardiology includes myocardial perfusion, viability assessment, inflammatory disease, infiltrative cardiomyopathy, coronary artery evaluation, structural-heart planning, and assessment of complex congenital conditions.

SPECT/CT remains widely used for myocardial perfusion, while cardiac PET is expanding in higher-acuity centers. CT, MRI, echocardiography, and nuclear medicine are increasingly interpreted as complementary tools. Multimodality platforms that connect imaging findings with intervention planning and longitudinal cardiovascular records will gain preference.

Musculoskeletal and Orthopedic Imaging

Musculoskeletal applications include bone metastasis assessment, infection localization, inflammatory disease, prosthetic complications, sports injuries, arthritis, and surgical planning.

SPECT/CT can improve anatomical localization of abnormal tracer uptake, while MRI and CT provide detailed soft-tissue and bone information. Image fusion is also used in selected spinal, orthopedic, and interventional procedures. Growth will be steady rather than exceptional, but the segment provides recurring demand across hospitals, orthopedic centers, and pain-management practices.

Other Clinical Applications

Other applications include endocrinology, infection and inflammation, renal disease, pulmonary disorders, pediatric imaging, transplant medicine, and image-guided biopsy or ablation.

These indications are individually smaller but collectively important. Their adoption is influenced by local specialist expertise, radiotracer availability, institutional research activity, and whether a health system can share a multimodality asset across several departments.

By Technology and Configuration

Fixed Integrated Systems

Fixed integrated systems dominate market revenue. This category includes permanently installed PET/CT, SPECT/CT, and PET/MRI platforms with shared patient tables, coordinated acquisition, integrated calibration, and dedicated processing environments.

These systems provide the highest workflow consistency but require substantial site preparation and capital approval. They are preferred by major hospitals, cancer centers, and facilities with predictable procedure volumes.

Sequential and Modular Systems

Sequential and modular configurations allow facilities to combine imaging components with greater installation flexibility. Some platforms can be upgraded through detector extensions, additional software, enhanced CT capability, or modular reconstruction packages.

This model appeals to health systems seeking to stage capital investment over several years. It can also protect against technology obsolescence by allowing selected components to be upgraded without replacing the entire platform.

Software-Based Multimodality Fusion

Software-based fusion integrates data acquired on separate scanners. It provides a lower-capital route to multimodality capability and is especially relevant for hospitals with mixed-vendor fleets.

Adoption is supported by oncology, neurology, radiation planning, and intervention. The principal purchasing criteria are registration accuracy, workflow simplicity, compatibility, cybersecurity, cloud architecture, and the ability to manage longitudinal examinations.

Mobile and Relocatable Systems

Mobile PET/CT and other relocatable configurations serve hospitals and regional markets that cannot initially support a permanently installed system. They allow several facilities to share equipment and can improve access in lower-density markets.

Growth is supported by regional oncology networks and providers seeking to test demand before making a fixed-site investment. Operational challenges include scheduling, transport, radiotracer coordination, weather exposure, state licensing, and service logistics.

AI-Enabled Quantitative Imaging Platforms

AI-enabled platforms span both hardware and software. They support reconstruction, noise reduction, attenuation correction, image registration, lesion segmentation, organ quantification, protocol automation, and longitudinal analysis.

Although AI does not form a mutually exclusive equipment category, it is becoming an important technology-based purchasing segment. Health systems increasingly assess whether AI functions are embedded in the acquisition platform, offered through enterprise software, or dependent on separate third-party contracts.

By End User

Hospitals and Integrated Health Systems

Hospitals and integrated health systems accounted for an estimated 58% of market revenue in 2025. They perform the largest share of high-acuity, inpatient, oncology, neurological, cardiovascular, and complex diagnostic examinations.

Large systems increasingly purchase through enterprise contracts and may standardize imaging technology across several hospitals. Their decisions are influenced by capital capacity, service reliability, cybersecurity, interoperability, physician preference, system uptime, and vendor support across the equipment lifecycle.

Freestanding Diagnostic Imaging Centers

Freestanding imaging centers represented approximately 21% of 2025 revenue. These providers emphasize utilization, appointment availability, patient experience, payer contracting, and cost control.

They are important buyers of PET/CT, MRI, CT, fusion software, and scalable digital platforms. Systems that require limited construction, provide predictable maintenance expense, and support extended operating hours are particularly attractive.

Cancer Centers and Radiation Oncology Facilities

Cancer centers accounted for approximately 11% of the market. Their requirements extend beyond diagnosis to staging, simulation, radiation planning, treatment response, recurrence evaluation, theranostics, and research.

These institutions frequently invest in premium PET/CT, quantitative SPECT/CT, dosimetry applications, treatment-planning integration, and advanced lesion-analysis software. Cancer-center demand is expected to grow faster than the general hospital segment.

Academic Medical Centers and Research Institutes

Academic centers represented approximately 7% of market revenue but exercise influence beyond their direct purchasing share. They conduct clinical trials, validate new radiotracers, develop protocols, train specialists, and generate evidence that supports wider adoption.

These institutions are the principal buyers of total-body PET/CT, PET/MRI, advanced neuroimaging, dynamic imaging, and research-oriented quantitative platforms. Their procurement decisions frequently prioritize scientific capability and data access in addition to clinical throughput.

Ambulatory Specialty and Physician-Owned Facilities

Ambulatory specialty facilities accounted for the remaining market share. This category includes cardiology practices, urology centers, orthopedic clinics, neurology practices, and image-guided intervention facilities.

Adoption is concentrated in cardiac SPECT, MRI-ultrasound fusion, targeted biopsy, and specialized visualization. Purchasing decisions are closely linked to procedure reimbursement, physician ownership economics, available space, and the ability to maintain high daily utilization.

Regional Insights: Where the Market Is Growing Fastest

The U.S. Multimodality Diagnostic Imaging Systems Market is geographically segmented into the South, Northeast, West, and Midwest. Regional performance differs according to population scale, cancer burden, age distribution, specialist density, hospital consolidation, academic research activity, outpatient imaging penetration, and the availability of radiopharmaceutical production and distribution.

The South represented the largest regional market in 2025, while the West is expected to post the fastest growth through 2035. The Northeast remains the most innovation-intensive region on a per-facility basis, and the Midwest provides a durable market supported by established health systems, major academic centers, and a significant medical-technology ecosystem.

South

The South accounted for an estimated USD 0.72 billion in 2025 and represented approximately 34% of the national market. The region includes Delaware, Maryland, Virginia, West Virginia, North Carolina, South Carolina, Georgia, Florida, Kentucky, Tennessee, Mississippi, Alabama, Oklahoma, Texas, Arkansas, Louisiana, and the District of Columbia.

The South’s leadership is supported by rapid population growth, major metropolitan expansion, a large older-adult population, high chronic disease prevalence, and continued investment in hospital and outpatient capacity. The region contains major medical markets in Houston, Dallas-Fort Worth, Austin, San Antonio, Miami, Tampa, Orlando, Jacksonville, Atlanta, Charlotte, Raleigh-Durham, Nashville, Baltimore, Richmond, and Northern Virginia.

Texas is the largest state opportunity in the region. Its population exceeds 31 million, and its major cities contain large academic centers, cancer institutes, integrated delivery networks, and freestanding imaging providers. Houston is especially important for oncology and molecular imaging because of its concentration of cancer care, research, and complex referral programs. Dallas-Fort Worth, Austin, and San Antonio are also expanding advanced imaging capacity as population and employer-sponsored insurance enrollment grow.

Texas buyers range from nationally recognized academic institutions to rural hospitals and investor-owned outpatient networks. This creates demand for both premium research-capable systems and scalable community-oriented PET/CT or SPECT/CT platforms. The state is also attractive for mobile and shared-service models because of its geographic size and uneven distribution of specialized imaging infrastructure.

Florida is another major demand center. The state’s large retirement-age population supports oncology, dementia, cardiovascular, orthopedic, and chronic-disease imaging. Miami, Tampa, Orlando, Jacksonville, Fort Lauderdale, and Southwest Florida contain substantial hospital and outpatient imaging networks. Florida providers are likely to prioritize patient throughput, short examination times, accessible system design, and efficient scheduling for older or medically complex patients.

Georgia and North Carolina are high-growth markets. Atlanta functions as a regional referral and business hub, while the Research Triangle supports academic medicine, biotechnology, and clinical research. Charlotte, Raleigh-Durham, Winston-Salem, and Greenville-Spartanburg are attracting health system expansion and specialty-care investment. These markets are well positioned for digital PET/CT, enterprise imaging, and oncology-focused multimodality platforms.

Tennessee has strategically important imaging markets in Nashville, Memphis, Knoxville, and Chattanooga. Nashville’s concentration of healthcare companies, hospital operators, and specialty providers makes the state influential in purchasing models and system-level contracting. Memphis supports advanced pediatric, oncology, and academic imaging, while Knoxville has a long-standing connection to nuclear medicine manufacturing and expertise.

Virginia and Maryland benefit from sophisticated health systems, federal research activity, defense-related medical infrastructure, and proximity to Washington, D.C. Baltimore, Northern Virginia, Richmond, and the District of Columbia support advanced oncology, neurological, cardiovascular, and research imaging. Procurement in these markets tends to be evidence-driven and heavily focused on cybersecurity, enterprise integration, and health-system interoperability.

South Carolina, Kentucky, Alabama, Louisiana, Arkansas, Mississippi, Oklahoma, and West Virginia have important regional medical centers but also face rural access constraints. These states represent opportunities for mobile PET/CT, remotely supported imaging operations, shared capital models, quantitative SPECT/CT, and hub-and-spoke oncology networks. Vendors that can combine reliable service with clinical education and flexible financing will be better positioned than those relying only on premium system performance.

The South is projected to reach approximately USD 1.62 billion by 2035. Growth will be supported by hospital expansion, cancer-center investment, outpatient imaging development, theranostics adoption, and replacement of aging nuclear medicine equipment.

Northeast

The Northeast represented an estimated USD 0.53 billion in 2025, equivalent to approximately 25% of the national market. The region includes Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, and Pennsylvania.

The Northeast is characterized by high specialist density, major academic medical centers, strong clinical-trial activity, and advanced adoption of complex imaging. It is an especially important market for PET/MRI, advanced brain imaging, oncology quantification, radiopharmaceutical research, cardiac imaging, and enterprise-level multimodality software.

New York is the largest state market in the region. New York City contains a dense concentration of academic hospitals, cancer centers, private imaging networks, and specialty practices. These institutions perform high volumes of oncology, neurological, cardiovascular, and surgical-planning imaging. The state also includes important markets in Long Island, Westchester County, Albany, Rochester, Syracuse, and Buffalo.

New York procurement is often influenced by space limitations, construction expense, operating efficiency, and the need to integrate equipment into complex urban hospital environments. Systems with compact footprints, high throughput, strong uptime, and scalable enterprise software can therefore compete effectively even when their purchase price is not the lowest.

Massachusetts has disproportionate strategic importance relative to its population. Boston’s medical and research ecosystem supports early adoption of advanced PET, MRI, neuroimaging, molecular diagnostics, and quantitative software. Academic institutions in the state are likely to evaluate total-body imaging, new radiotracers, AI algorithms, and cross-modality biomarker development before these technologies achieve broader commercial penetration.

Pennsylvania provides a large and diverse market across Philadelphia, Pittsburgh, central Pennsylvania, and regional community systems. Philadelphia supports major academic, pediatric, cancer, and neurological programs, while Pittsburgh has an established history in PET/CT and advanced imaging development. Pennsylvania also offers a substantial base of community hospitals that require cost-effective replacement systems and enterprise connectivity.

New Jersey benefits from high population density, pharmaceutical and biotechnology activity, strong oncology demand, and proximity to New York and Philadelphia. The state is an attractive market for imaging centers, cancer programs, clinical trials, and multimodality software supporting treatment development.

Connecticut and Rhode Island have smaller populations but sophisticated provider systems and strong access to specialty medicine. New Hampshire, Vermont, and Maine are more dispersed and contain rural access challenges. These states provide opportunities for regional imaging networks, mobile platforms, cloud-based interpretation, and software that allows smaller facilities to connect with tertiary specialists.

The Northeast is projected to reach approximately USD 1.16 billion by 2035. Its overall growth rate will be moderated by market maturity and slower population expansion, but it will remain one of the most profitable regions because of high-value case complexity, premium system adoption, research investment, and advanced specialist utilization.

West

The West accounted for an estimated USD 0.49 billion in 2025 and is forecast to become the fastest-growing U.S. region. It includes Montana, Idaho, Wyoming, Colorado, New Mexico, Arizona, Utah, Nevada, Washington, Oregon, California, Alaska, and Hawaii.

California dominates the regional market because of its population scale, major academic institutions, cancer centers, technology ecosystem, and extensive outpatient imaging sector. Los Angeles, San Diego, San Francisco, Sacramento, Orange County, and the Silicon Valley region contain high concentrations of advanced imaging demand.

California is particularly important for total-body PET, AI-enabled imaging, advanced neurology, precision oncology, clinical research, and private-pay preventive imaging. The state also supports software companies, digital-health developers, imaging-service networks, and venture-backed diagnostic businesses. These factors accelerate the commercialization of technologies that combine imaging equipment with cloud analytics and longitudinal health data.

California providers face high labor, construction, utility, and regulatory costs. Systems that reduce examination time, automate complex protocols, lower energy consumption, or support remote operational assistance can therefore create substantial economic value. The state’s large geography also supports mobile and distributed imaging models outside its largest metropolitan areas.

Washington and Oregon are influential markets for integrated healthcare delivery and evidence-based technology adoption. Seattle contains major academic and research institutions, while Portland supports sophisticated regional health systems. Providers in these states often emphasize interoperability, data governance, patient access, and population-health integration.

Arizona and Nevada are among the most attractive growth markets because of population expansion, aging demographics, and development of new hospital and outpatient facilities. Phoenix, Tucson, Las Vegas, and Reno are adding oncology, cardiovascular, neurological, and orthopedic capacity. Nevada has also served as an early U.S. installation location for advanced digital PET/CT technology, demonstrating the willingness of large outpatient imaging operators to invest in differentiated equipment.

Colorado and Utah combine population growth with strong integrated health systems and research-oriented providers. Denver, Boulder, Colorado Springs, and Salt Lake City are important markets for oncology, neurological, and sports-medicine imaging. Utah also has an established medical-device and healthcare technology base that can support clinical collaboration.

New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii are smaller markets with significant geographic access challenges. Their opportunity lies in mobile imaging, regional referral networks, shared-service systems, remote support, and cloud-based specialist interpretation. Equipment reliability is especially important because service delays can have a greater operational impact in remote locations.

The West is expected to reach approximately USD 1.23 billion by 2035. Growth will be driven by population migration, technology adoption, AI integration, total-body imaging, digital PET/CT replacement, and expansion of outpatient diagnostic networks.

Midwest

The Midwest represented an estimated USD 0.38 billion in 2025, accounting for approximately 18% of the national market. The region includes Ohio, Indiana, Illinois, Michigan, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota.

The Midwest provides a stable market supported by large regional health systems, community hospital networks, academic medicine, cancer programs, and a significant burden of chronic disease. The region’s procurement culture often places strong emphasis on service reliability, measurable clinical benefit, standardized contracts, and long-term ownership cost.

Illinois is the largest state opportunity, led by Chicago’s academic hospitals, cancer centers, private imaging groups, and integrated delivery networks. The state also contains substantial community-hospital demand outside Chicago. Large systems may seek enterprise agreements covering scanners, software, service, and multiple facilities.

Ohio is strategically important because of its major healthcare institutions and strong specialist referral networks in Cleveland, Columbus, Cincinnati, Dayton, and other metropolitan areas. The state supports advanced oncology, cardiovascular imaging, neurological imaging, and clinical research. Ohio providers can influence broader adoption through physician training and evidence generation.

Michigan has significant demand in Detroit, Ann Arbor, Grand Rapids, and regional hospital markets. The state offers opportunities in oncology, cardiac imaging, neuroimaging, and equipment replacement. Wisconsin supports major academic and integrated systems in Madison, Milwaukee, and other regional centers.

Minnesota is particularly important because of its medical-technology heritage and concentration of advanced healthcare expertise. Minneapolis-Saint Paul and Rochester support high-acuity imaging, research, and complex referral medicine. The state can serve as an early evaluation market for quantitative imaging and enterprise integration.

Indiana and Missouri provide stable demand across Indianapolis, St. Louis, Kansas City, and community markets. Iowa, Kansas, Nebraska, North Dakota, and South Dakota have smaller urban populations but extensive rural catchment areas. Hub-and-spoke networks, mobile imaging, shared capital arrangements, and cloud-based multimodality interpretation are relevant to these states.

The Midwest is expected to reach approximately USD 0.85 billion by 2035. Growth will be steady, supported by replacement demand, cancer-care investment, clinical network consolidation, quantitative SPECT/CT, and expansion of advanced imaging beyond major academic centers.

Key Market Players

The U.S. Multimodality Diagnostic Imaging Systems Competitive Landscape is moderately consolidated in capital equipment and more fragmented in software, advanced visualization, image fusion, and specialized nuclear medicine technology.

GE HealthCare, Siemens Healthineers, and Philips hold strong positions because of their broad portfolios across CT, MRI, PET/CT, SPECT/CT, ultrasound, advanced visualization, service, and enterprise imaging. Canon Medical Systems USA, United Imaging Healthcare, and Fujifilm Healthcare Americas are increasing competitive pressure through portfolio expansion, digital technology, pricing flexibility, and alternative contracting models.

Specialized companies compete in solid-state nuclear medicine, mobile imaging, PET technology, quantitative processing, multimodality fusion, dosimetry, cloud-based enterprise imaging, and vendor-neutral visualization. Competition is increasingly based on the total clinical and operational ecosystem rather than a single scanner specification.

Some of the key players in the U.S. Multimodality Diagnostic Imaging Systems industry are:

GE HealthCare
Siemens Healthineers
Philips
Canon Medical Systems USA
United Imaging Healthcare
Fujifilm Healthcare Americas
Shimadzu Medical Systems USA
Mediso USA
Spectrum Dynamics Medical
NeuroLogica Corporation
Esaote North America
Bruker Corporation
Cubresa
Positron Corporation
MiE America
Digirad Health
MIM Software
Mirada Medical
Hermes Medical Solutions
Sectra
Intelerad
Visage Imaging
TeraRecon
Agfa HealthCare

GE HealthCare has strengthened its multimodality strategy by combining imaging equipment, pharmaceutical diagnostics, digital workflow, and the capabilities of MIM Software. Siemens Healthineers remains deeply established in PET/CT, SPECT/CT, MRI, CT, and advanced molecular-imaging applications. Philips competes through spectral CT, MRI, image-guided care, enterprise informatics, and AI-enabled workflow.

Canon Medical maintains a broad U.S. imaging portfolio and supports multimodality visualization through advanced software capabilities. United Imaging is expanding its U.S. presence with digital PET/CT, CT, MRI, and scalable system architectures. Spectrum Dynamics, Mediso, MiE America, and Digirad participate in specialized nuclear medicine and cardiac imaging categories.

Sectra, Intelerad, Visage Imaging, Agfa HealthCare, TeraRecon, Hermes Medical Solutions, Mirada Medical, and MIM Software influence the software layer of competition. Their platforms help providers manage images from different manufacturers, perform registration and quantification, compare serial studies, and integrate multimodality data into clinical workflows.

Market share through 2035 will be influenced by FDA clearances, detector performance, clinical evidence, AI reliability, radiotracer compatibility, installation capacity, cybersecurity, service coverage, financing flexibility, and access to enterprise-level contracts. Vendors that demonstrate higher throughput, lower radiotracer use, fewer repeat scans, reliable quantification, and stronger cross-facility standardization will be best positioned to defend premium pricing.

Recent Developments

Recent developments in the U.S. Multimodality Diagnostic Imaging Systems Market show that competition is moving toward AI-assisted reconstruction, quantitative molecular imaging, spectral data, longer axial fields of view, and integrated software ecosystems.

In April 2024, GE HealthCare completed its acquisition of MIM Software. The transaction strengthened GE HealthCare’s capabilities in multimodality image analysis, radiation oncology, molecular radiotherapy, diagnostic imaging, urology, and workflow automation. The strategic importance of the acquisition lies in connecting equipment, pharmaceutical diagnostics, advanced visualization, and longitudinal care pathways.

During 2024, United Imaging announced the first U.S. installation of its uMI Panvivo digital PET/CT platform at an imaging provider in Nevada. The deployment demonstrated increasing competition in the U.S. molecular-imaging market and highlighted demand from outpatient operators for high-resolution, scalable digital PET/CT systems.

In 2025, FDA clearances for multimodality image-processing and fusion applications continued to expand. Cleared platforms demonstrated support for CT, MRI, PET, SPECT, ultrasound, functional imaging, and three-dimensional or four-dimensional visualization. These developments indicate that multimodality competition is broadening from integrated scanner hardware toward vendor-neutral software and clinical workflow.

Philips received U.S. clearance in 2025 for SmartSpeed Precise, a dual-AI MRI acceleration technology intended to improve imaging speed and precision across its 1.5T and 3.0T MRI portfolio. Such installed-base software upgrades are commercially important because they allow health systems to improve productivity without replacing every scanner.

GE HealthCare continued to expand AI-enabled molecular-imaging capabilities, including deep-learning-based PET image processing and multimodality workflow applications. These technologies are intended to improve image quality, contrast recovery, quantitative consistency, and reading efficiency.

In April 2026, Philips received FDA clearance for its Verida detector-based spectral CT platform in the United States. Spectral CT is strategically relevant to multimodality imaging because it can generate material-specific information that complements PET, MRI, ultrasound, and treatment-planning data.

The market is also being shaped by the expansion of PSMA imaging, amyloid-related imaging workflows, neuroendocrine tumor imaging, radiopharmaceutical therapy, and post-treatment dosimetry. These care pathways require closer coordination between imaging equipment, radiotracers, quantitative software, radiation safety, treatment planning, and longitudinal reporting.

Competition is expected to intensify as manufacturers introduce longer-field PET systems, improve digital detector sensitivity, expand AI applications, and provide upgradeable architectures. Partnerships between equipment vendors, software developers, radiopharmaceutical companies, academic centers, and health systems will become increasingly important.

Conclusion

The U.S. Multimodality Diagnostic Imaging Systems Market Size and Share is positioned to expand from approximately USD 2.12 billion in 2025 to USD 4.86 billion by 2035, representing a CAGR of 8.65% during the 2026–2035 forecast period.

The market’s long-term strength is supported by cancer incidence, neurological disease, cardiovascular complexity, hospital equipment replacement, precision medicine, radiopharmaceutical innovation, and the need to integrate anatomical and functional information. Multimodality imaging will become increasingly important as clinical pathways require more precise patient selection, quantitative treatment monitoring, and longitudinal disease assessment.

PET/CT will remain the largest system category, supported by oncology and theranostics. SPECT/CT will maintain a broad role in nuclear medicine and cardiac imaging. PET/MRI will grow from a smaller base in neurology, pediatrics, pelvic oncology, and research. Image-fusion and enterprise-analysis platforms will expand rapidly because they allow health systems to connect equipment from different manufacturers and standardize interpretation across facilities.

Hospitals and integrated health systems will remain the largest end-user group, but freestanding imaging centers and specialty cancer providers will gain influence. Academic institutions will continue to shape technology adoption through research, radiotracer development, protocol validation, and specialist training.

The South will remain the largest regional market because of population scale, hospital expansion, and disease burden. The West will record the fastest growth due to technology adoption, population migration, and outpatient imaging development. The Northeast will remain the highest-acuity and most research-intensive region, while the Midwest will provide stable demand supported by mature provider networks and capital replacement.

For manufacturers, investors, health systems, imaging-center operators, and radiopharmaceutical stakeholders, the central strategic issue is not simply whether imaging volume will rise. The more important question is which platforms can convert increasing diagnostic complexity into clinically useful, reproducible, and economically sustainable information.

The winning systems will be those that connect acquisition, reconstruction, fusion, quantification, reporting, treatment planning, and longitudinal monitoring. Vendors that can demonstrate measurable improvements in throughput, radiotracer efficiency, diagnostic confidence, repeat-scan reduction, staff productivity, and enterprise interoperability will define the next phase of the U.S. multimodality diagnostic imaging systems industry.

TABLE OF CONTENT

1. U.S. Multimodality Diagnostic Imaging Systems Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Multimodality Diagnostic Imaging System Manufacturers
1.6.2. Detector, Magnet, Gantry, Software, and Component Suppliers
1.6.3. Hospitals and Integrated Delivery Networks
1.6.4. Diagnostic Imaging Centers and Radiology Networks
1.6.5. Cancer Centers and Radiation Oncology Facilities
1.6.6. Academic Medical Centers and Research Institutes
1.6.7. Nuclear Medicine and Radiopharmacy Service Providers
1.6.8. Group Purchasing Organizations, Distributors, and Equipment Resellers
1.6.9. Payers, Regulators, Radiologists, and Clinical Decision-Makers

What this section provides: This section defines the market boundary, included imaging systems, revenue scope, research methodology, study assumptions, and stakeholder ecosystem used to measure and validate the U.S. multimodality diagnostic imaging systems market.

2. U.S. Multimodality Diagnostic Imaging Systems Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size Projection: USD 2.12 Billion in 2025 to USD 4.86 Billion by 2035
2.8. Forecast CAGR Analysis, 2026–2035
2.9. High-Growth System and Application Opportunities
2.10. Key Investment and Procurement Takeaways

What this section provides: This section gives decision-makers a concise view of historical performance, 2025 market positioning, forecast growth, leading technologies, application priorities, regional opportunities, and competitive intensity.

3. U.S. Multimodality Diagnostic Imaging Systems Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Cancer Incidence and Longitudinal Oncology Imaging Demand
3.1.2. Expansion of Precision Oncology and Radiopharmaceutical Theranostics
3.1.3. Growing Neurological and Neurodegenerative Disease Imaging Requirements
3.1.4. Increasing Adoption of Integrated Cardiovascular Imaging Pathways
3.1.5. Replacement of Aging PET/CT, SPECT/CT, MRI, and Nuclear Medicine Infrastructure
3.1.6. Growth of AI-Assisted Reconstruction, Fusion, and Quantitative Imaging
3.1.7. Expansion of Outpatient and Freestanding Diagnostic Imaging Networks
3.1.8. Increasing Demand for Lower-Dose and Faster-Throughput Imaging
3.2. Restraints and Their Impact Analysis
3.2.1. High Capital Acquisition and Installation Costs
3.2.2. Complex Site Planning, Shielding, Cooling, and Facility Requirements
3.2.3. Reimbursement Pressure and Imaging Utilization Management
3.2.4. Shortage of Nuclear Medicine Technologists, Radiologists, and Medical Physicists
3.2.5. Radiopharmaceutical Availability and Distribution Constraints
3.2.6. Interoperability, Cybersecurity, and Data-Governance Concerns
3.3. Opportunities and Their Impact Analysis
3.3.1. Digital PET/CT and Extended-Axial-Field-of-View Systems
3.3.2. Total-Body PET/CT Adoption in Academic and High-Volume Centers
3.3.3. Quantitative SPECT/CT and Theranostics Dosimetry
3.3.4. PET/MRI Expansion in Neurology, Pediatrics, and Pelvic Oncology
3.3.5. Vendor-Neutral Multimodality Image-Fusion Platforms
3.3.6. AI-Based Lesion Detection, Segmentation, and Longitudinal Tracking
3.3.7. Mobile, Relocatable, and Shared-Service Imaging Models
3.3.8. Managed Equipment Services and Subscription-Based Software Models
3.4. Challenges and Their Impact Analysis
3.4.1. Extended Hospital Capital Approval Cycles
3.4.2. Clinical Evidence Requirements for Premium Technology Adoption
3.4.3. Workflow Standardization Across Mixed-Vendor Imaging Fleets
3.4.4. Balancing Image Quality, Scan Time, Radiation Dose, and Operating Cost
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Imaging Department Productivity and Throughput Analysis
3.8. Hospital Capital Procurement Behavior Analysis
3.9. Equipment Replacement Cycle and Installed-Base Analysis
3.10. Total Cost of Ownership Analysis
3.11. Radiopharmaceutical Supply and Imaging Capacity Analysis

What this section provides: This section evaluates the clinical, commercial, reimbursement, staffing, technology, and operational forces shaping multimodality imaging demand and helps clients assess both market upside and implementation risk.

4. U.S. Multimodality Diagnostic Imaging Systems Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Imaging System Component and Detector Supply Analysis
4.6. Impact of Digitalization and Enterprise Imaging
4.7. Application & Innovation Landscape
4.8. FDA Regulatory Framework Analysis
4.9. CMS Reimbursement and Coverage Landscape
4.10. Radiopharmaceutical Regulatory and Distribution Environment
4.11. Import, Export, and Tariff Impact Analysis
4.12. Government Initiatives and Public Health Programs
4.13. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.14. Hospital Value Analysis Committee Decision Framework
4.15. Cybersecurity, HIPAA, and Imaging Data-Governance Analysis
4.16. Sustainability, Energy Consumption, and Equipment Lifecycle Analysis

What this section provides: This section gives clients a complete view of the regulatory, reimbursement, pricing, supply-chain, technology, cybersecurity, sustainability, and procurement environment influencing the U.S. multimodality diagnostic imaging systems industry.

5. U.S. Multimodality Diagnostic Imaging Systems Market – By System Type

5.1. Overview
5.1.1. Segment Share Analysis, By System Type, 2025 & 2035 (%)
5.1.2. PET/CT Systems
5.1.2.1. Conventional PET/CT Systems
5.1.2.2. Digital PET/CT Systems
5.1.2.3. Extended-Axial-Field-of-View PET/CT Systems
5.1.2.4. Total-Body PET/CT Systems
5.1.2.5. Mobile and Relocatable PET/CT Systems
5.1.3. SPECT/CT Systems
5.1.3.1. General-Purpose SPECT/CT Systems
5.1.3.2. Cardiac SPECT/CT Systems
5.1.3.3. Quantitative SPECT/CT Systems
5.1.3.4. Solid-State Detector SPECT/CT Systems
5.1.4. PET/MRI Systems
5.1.4.1. Integrated Whole-Body PET/MRI Systems
5.1.4.2. Brain and Neurology PET/MRI Systems
5.1.4.3. Oncology and Pediatric PET/MRI Systems
5.1.5. Multimodality Image-Fusion and Analysis Platforms
5.1.5.1. PET/CT and PET/MRI Analysis Platforms
5.1.5.2. CT/MRI Image-Fusion Platforms
5.1.5.3. SPECT/CT Quantification Platforms
5.1.5.4. Ultrasound/MRI and Ultrasound/CT Fusion Platforms
5.1.5.5. Enterprise Vendor-Neutral Multimodality Platforms
5.1.6. Other Integrated Hybrid Imaging Systems
5.1.6.1. MRI-Ultrasound Fusion Systems
5.1.6.2. CT-Angiography Integrated Systems
5.1.6.3. Multimodality Neuroimaging Systems
5.1.6.4. Image-Guided Intervention Platforms

What this section provides: This section identifies the multimodality system categories expected to generate the highest revenue, strongest replacement demand, and fastest technology adoption through 2035.

6. U.S. Multimodality Diagnostic Imaging Systems Market – By Clinical Application

6.1. Overview
6.1.1. Segment Share Analysis, By Clinical Application, 2025 & 2035 (%)
6.1.2. Oncology
6.1.2.1. Cancer Detection and Diagnosis
6.1.2.2. Tumor Staging and Restaging
6.1.2.3. Radiation Therapy Planning
6.1.2.4. Treatment-Response Assessment
6.1.2.5. Recurrence and Surveillance Imaging
6.1.2.6. Theranostics Patient Selection and Dosimetry
6.1.3. Neurology
6.1.3.1. Alzheimer’s Disease and Cognitive Disorders
6.1.3.2. Parkinson’s Disease and Movement Disorders
6.1.3.3. Epilepsy
6.1.3.4. Brain Tumors
6.1.3.5. Multiple Sclerosis and Neuroinflammation
6.1.3.6. Stroke and Cerebrovascular Imaging
6.1.4. Cardiology
6.1.4.1. Myocardial Perfusion Imaging
6.1.4.2. Myocardial Viability Assessment
6.1.4.3. Coronary Artery Disease Evaluation
6.1.4.4. Structural Heart Planning
6.1.4.5. Inflammatory and Infiltrative Cardiac Disease
6.1.4.6. Congenital Heart Disease
6.1.5. Musculoskeletal and Orthopedic Imaging
6.1.5.1. Bone Metastasis Assessment
6.1.5.2. Infection and Inflammation Localization
6.1.5.3. Prosthetic Joint and Implant Evaluation
6.1.5.4. Spine and Sports Injury Imaging
6.1.5.5. Image-Guided Musculoskeletal Procedures
6.1.6. Other Clinical Applications
6.1.6.1. Endocrinology
6.1.6.2. Renal and Urological Imaging
6.1.6.3. Pulmonary Imaging
6.1.6.4. Pediatric Imaging
6.1.6.5. Infection and Inflammation Imaging
6.1.6.6. Transplant and Image-Guided Intervention

What this section provides: This section evaluates multimodality imaging demand by clinical use case and helps clients prioritize applications with strong procedure growth, specialist adoption, reimbursement relevance, and technology intensity.

7. U.S. Multimodality Diagnostic Imaging Systems Market – By Technology and Configuration

7.1. Overview
7.1.1. Segment Share Analysis, By Technology and Configuration, 2025 & 2035 (%)
7.1.2. Fixed Integrated Systems
7.1.2.1. Permanently Installed PET/CT Systems
7.1.2.2. Permanently Installed SPECT/CT Systems
7.1.2.3. Permanently Installed PET/MRI Systems
7.1.3. Sequential and Modular Systems
7.1.3.1. Modular Detector Architectures
7.1.3.2. Upgradeable Gantry and Reconstruction Platforms
7.1.3.3. Staged Hardware and Software Configurations
7.1.4. Software-Based Multimodality Fusion
7.1.4.1. On-Premise Fusion Software
7.1.4.2. Cloud-Based Fusion Software
7.1.4.3. Vendor-Neutral Enterprise Platforms
7.1.4.4. Treatment-Planning and Dosimetry Integration
7.1.5. Mobile and Relocatable Systems
7.1.5.1. Mobile PET/CT
7.1.5.2. Shared-Service Nuclear Medicine Systems
7.1.5.3. Relocatable and Modular Imaging Suites
7.1.6. AI-Enabled Quantitative Imaging Platforms
7.1.6.1. AI-Assisted Image Reconstruction
7.1.6.2. Automated Registration and Fusion
7.1.6.3. Lesion Detection and Segmentation
7.1.6.4. Longitudinal Disease Tracking
7.1.6.5. Quantitative Biomarker and Dosimetry Analysis

What this section provides: This section evaluates the system configurations, software architectures, mobile models, and AI capabilities changing multimodality image acquisition, interpretation, quantification, and clinical workflow.

8. U.S. Multimodality Diagnostic Imaging Systems Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.1.2. Hospitals and Integrated Health Systems
8.1.2.1. Large Integrated Delivery Networks
8.1.2.2. Community Hospitals
8.1.2.3. Specialty Hospitals
8.1.2.4. Government and Veterans Healthcare Facilities
8.1.3. Freestanding Diagnostic Imaging Centers
8.1.3.1. Independent Imaging Centers
8.1.3.2. Multi-State Imaging Networks
8.1.3.3. Hospital-Affiliated Outpatient Imaging Centers
8.1.4. Cancer Centers and Radiation Oncology Facilities
8.1.4.1. Comprehensive Cancer Centers
8.1.4.2. Community Oncology Networks
8.1.4.3. Radiation Therapy and Theranostics Centers
8.1.5. Academic Medical Centers and Research Institutes
8.1.5.1. University Hospitals
8.1.5.2. Clinical Research Institutes
8.1.5.3. Molecular Imaging and Radiopharmaceutical Research Centers
8.1.6. Ambulatory Specialty and Physician-Owned Facilities
8.1.6.1. Cardiology Practices
8.1.6.2. Neurology Centers
8.1.6.3. Urology and Prostate Imaging Centers
8.1.6.4. Orthopedic and Image-Guided Intervention Centers

What this section provides: This section explains which U.S. care settings and customer groups are expected to drive capital purchasing, system utilization, software adoption, and recurring imaging demand.

9. U.S. Multimodality Diagnostic Imaging Systems Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.1.2. Direct Hospital and Health System Procurement
9.1.3. Integrated Delivery Network Enterprise Contracts
9.1.4. Group Purchasing Organization Contracts
9.1.5. Distributor, Reseller, and Refurbished Equipment Channels
9.1.6. Leasing and Equipment Financing
9.1.7. Managed Equipment Service Agreements
9.1.8. Mobile and Shared-Service Procurement
9.1.9. Software Subscription and Cloud-Based Licensing

What this section provides: This section explains how multimodality diagnostic imaging systems and software are purchased in the U.S., including direct contracts, GPO agreements, leasing, managed services, reseller channels, and subscription-based procurement.

10. U.S. Multimodality Diagnostic Imaging Systems Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Installed-Base and Equipment Replacement Analysis
10.1.4. Regional Imaging Procedure Volume Analysis
10.1.5. Regional Cancer, Neurology, and Cardiovascular Imaging Demand
10.1.6. Regional Radiopharmaceutical Availability and Distribution Analysis
10.1.7. Regional Reimbursement and Procurement Dynamics
10.1.8. Regional Academic Medical Center and Research Ecosystem Analysis

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Imaging System Manufacturers, Distributors, and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.9. California

10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.10. Washington

10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.11. Arizona

10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.12. Colorado

10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.13. Oregon

10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.14. Utah

10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.15. Nevada

10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.16. New Mexico

10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.17. Idaho

10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.18. Montana

10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.19. Wyoming

10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.20. Alaska

10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.21. Hawaii

10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Imaging System Manufacturers, Distributors, and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.9. New York

10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.10. Massachusetts

10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.11. New Jersey

10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania

10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.13. Connecticut

10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.14. Maine

10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.15. Vermont

10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.16. New Hampshire

10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.17. Rhode Island

10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Imaging System Manufacturers, Distributors, and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.9. Texas

10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.10. Florida

10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.11. Georgia

10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.12. North Carolina

10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.13. Tennessee

10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.14. South Carolina

10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.15. Alabama

10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.16. Mississippi

10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.17. Louisiana

10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.18. Arkansas

10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.19. Kentucky

10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.20. Oklahoma

10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.21. Virginia

10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.22. Maryland

10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.23. West Virginia

10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.24. Delaware

10.4.24.1. Overview
10.4.24.2. Delaware Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.24.3. Delaware Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.24.4. Delaware Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.24.5. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.24.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.25. District of Columbia

10.4.25.1. Overview
10.4.25.2. District of Columbia Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.4.25.3. District of Columbia Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.25.4. District of Columbia Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.4.25.5. District of Columbia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.25.6. District of Columbia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Imaging System Manufacturers, Distributors, and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.9. Illinois

10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.10. Ohio

10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.11. Michigan

10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.12. Minnesota

10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.13. Indiana

10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.14. Wisconsin

10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.15. Missouri

10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.16. Iowa

10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.17. Kansas

10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.18. Nebraska

10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.19. North Dakota

10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.20. South Dakota

10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By System Type, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By Technology and Configuration, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

What this section provides: This section delivers regional and state-level analysis across all 50 states, helping clients identify imaging-capacity hubs, replacement opportunities, advanced-technology adoption hotspots, radiopharmaceutical access patterns, and priority commercial territories.

11. U.S. Multimodality Diagnostic Imaging Systems Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Market Concentration and Competitive Intensity Analysis
11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. Innovators
11.3.4. Emerging and Specialized Players
11.4. Product Portfolio Benchmarking
11.5. Technology and Detector Capability Benchmarking
11.6. AI, Software, and Enterprise Imaging Benchmarking
11.7. Service Network and Installed-Base Benchmarking
11.8. Company Profiles

11.8.1. GE HealthCare
11.8.2. Siemens Healthineers
11.8.3. Philips
11.8.4. Canon Medical Systems USA
11.8.5. United Imaging Healthcare
11.8.6. Fujifilm Healthcare Americas
11.8.7. Shimadzu Medical Systems USA
11.8.8. Samsung NeuroLogica
11.8.9. Mediso USA
11.8.10. Spectrum Dynamics Medical
11.8.11. Esaote North America
11.8.12. Bruker Corporation
11.8.13. Cubresa
11.8.14. Positron Corporation
11.8.15. MiE America
11.8.16. Digirad Health
11.8.17. MIM Software
11.8.18. Mirada Medical
11.8.19. Hermes Medical Solutions
11.8.20. Sectra
11.8.21. Intelerad
11.8.22. Visage Imaging
11.8.23. TeraRecon
11.8.24. Agfa HealthCare
11.8.25. Carestream Health

Note: Each company profile will include company overview, multimodality imaging portfolio, U.S. installed-base strategy, product positioning, detector and software capabilities, service model, financial positioning, FDA clearances, partnerships, acquisitions, clinical collaborations, and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, portfolio positioning, detector and software comparisons, service-network analysis, innovation direction, and strategic intelligence on leading multimodality imaging companies.

12. U.S. Multimodality Diagnostic Imaging Systems Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Digital PET Detector Technology
12.2.2. Total-Body and Long-Axial-Field-of-View PET/CT
12.2.3. Quantitative SPECT/CT
12.2.4. Advanced PET/MRI
12.2.5. Photon-Counting and Spectral CT Integration
12.2.6. AI-Assisted Reconstruction and Multimodality Fusion
12.2.7. Automated Lesion Segmentation and Longitudinal Tracking
12.2.8. Theranostics Dosimetry and Molecular Imaging Platforms
12.2.9. Cloud-Based Enterprise Imaging and Vendor-Neutral Archives
12.3. Emerging Business Trends
12.3.1. Imaging-as-a-Service Models
12.3.2. Managed Equipment Services
12.3.3. Subscription-Based Software and AI Licensing
12.3.4. Mobile and Shared-Service Imaging Expansion
12.3.5. Consolidation of Outpatient Imaging Networks
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. Technology Adoption Roadmap, 2026–2035
12.7. Future Hospital Procurement and Replacement Outlook

What this section provides: This section prepares clients for technology disruption, market-structure changes, capital replacement cycles, business-model evolution, and high-value investment opportunities through 2035.

13. U.S. Multimodality Diagnostic Imaging Systems Market: Strategic Recommendations

13.1. Recommendations for Imaging System Manufacturers
13.2. Recommendations for Software and AI Platform Developers
13.3. Recommendations for Hospitals and Integrated Health Systems
13.4. Recommendations for Diagnostic Imaging Center Operators
13.5. Recommendations for Cancer Centers and Theranostics Providers
13.6. Recommendations for Investors and Private Equity Firms
13.7. Recommendations for Distributors, Resellers, and Channel Partners
13.8. Recommendations for New Entrants and Startups
13.9. Go-to-Market Strategy Considerations
13.10. Product Positioning and Portfolio Expansion Guidance
13.11. Hospital Value-Proposition Development
13.12. Geographic Expansion and State Prioritization Strategy
13.13. Partnership, Acquisition, and Clinical Collaboration Strategy
13.14. Pricing, Financing, and Managed-Service Strategy

What this section provides: This section converts market intelligence into actionable recommendations for portfolio planning, product positioning, commercialization, financing, geographic expansion, investment decisions, and competitive differentiation.

14. U.S. Multimodality Diagnostic Imaging Systems Market: Disclaimer

14.1. Scope Limitation
14.2. Market Definition and Inclusion Limitation
14.3. Data Use Limitation
14.4. Forecasting Limitation
14.5. Legal Disclaimer
14.6. Third-Party Data Disclaimer
14.7. Company and Product Information Disclaimer
14.8. Regulatory and Reimbursement Disclaimer

What this section provides: This section clarifies the report’s market boundaries, methodological limitations, legal conditions, third-party data use, and assumptions associated with long-term market forecasts.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Multimodality Diagnostic Imaging Systems Market: Market Definition and Scope
TABLE 3: U.S. Multimodality Diagnostic Imaging Systems Market: Revenue Inclusion and Exclusion Framework
TABLE 4: U.S. Multimodality Diagnostic Imaging Systems Market: Research Methodology Framework
TABLE 5: U.S. Multimodality Diagnostic Imaging Systems Market: Primary Data Collection Framework
TABLE 6: U.S. Multimodality Diagnostic Imaging Systems Market: Secondary Data Sourcing Framework
TABLE 7: U.S. Multimodality Diagnostic Imaging Systems Market: Analytical Frameworks and Forecasting Models
TABLE 8: U.S. Multimodality Diagnostic Imaging Systems Market: Data Validation and Publishing Process
TABLE 9: U.S. Multimodality Diagnostic Imaging Systems Market: Key Assumptions
TABLE 10: U.S. Multimodality Diagnostic Imaging Systems Market: Market Ecosystem Overview
TABLE 11: U.S. Multimodality Diagnostic Imaging Systems Market: Stakeholder Analysis
TABLE 12: U.S. Multimodality Diagnostic Imaging Systems Market: Key Terminology and System Classification
TABLE 13: U.S. Multimodality Diagnostic Imaging Systems Market: Executive Summary Snapshot, 2025
TABLE 14: U.S. Multimodality Diagnostic Imaging Systems Market: Analyst Viewpoint Summary
TABLE 15: U.S. Multimodality Diagnostic Imaging Systems Market: Market Attractiveness Index
TABLE 16: U.S. Multimodality Diagnostic Imaging Systems Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 17: U.S. Multimodality Diagnostic Imaging Systems Market: Base Year Market Positioning, 2025
TABLE 18: U.S. Multimodality Diagnostic Imaging Systems Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 19: U.S. Multimodality Diagnostic Imaging Systems Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 20: U.S. Multimodality Diagnostic Imaging Systems Market: CAGR Analysis, 2026–2035 (%)
TABLE 21: U.S. Multimodality Diagnostic Imaging Systems Market: High-Growth Opportunity Areas
TABLE 22: U.S. Multimodality Diagnostic Imaging Systems Market: Key Investment and Procurement Takeaways
TABLE 23: U.S. Multimodality Diagnostic Imaging Systems Market: Drivers; Impact Analysis
TABLE 24: U.S. Multimodality Diagnostic Imaging Systems Market: Restraints; Impact Analysis
TABLE 25: U.S. Multimodality Diagnostic Imaging Systems Market: Opportunities; Impact Analysis
TABLE 26: U.S. Multimodality Diagnostic Imaging Systems Market: Challenges; Impact Analysis
TABLE 27: U.S. Multimodality Diagnostic Imaging Systems Market: Patent & Innovation Analysis, 2021–2025
TABLE 28: U.S. Multimodality Diagnostic Imaging Systems Market: Clinical Workflow Economics Matrix
TABLE 29: U.S. Multimodality Diagnostic Imaging Systems Market: Imaging Department Productivity and Throughput Matrix
TABLE 30: U.S. Multimodality Diagnostic Imaging Systems Market: Hospital Capital Procurement Behavior Matrix
TABLE 31: U.S. Multimodality Diagnostic Imaging Systems Market: Equipment Replacement Cycle and Installed-Base Analysis
TABLE 32: U.S. Multimodality Diagnostic Imaging Systems Market: Total Cost of Ownership Analysis
TABLE 33: U.S. Multimodality Diagnostic Imaging Systems Market: Radiopharmaceutical Supply and Imaging Capacity Analysis
TABLE 34: U.S. Multimodality Diagnostic Imaging Systems Market: PESTEL Analysis
TABLE 35: U.S. Multimodality Diagnostic Imaging Systems Market: Porter’s Five Forces Analysis
TABLE 36: U.S. Multimodality Diagnostic Imaging Systems Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 37: U.S. Multimodality Diagnostic Imaging Systems Market: Value Chain Analysis
TABLE 38: U.S. Multimodality Diagnostic Imaging Systems Market: Supply Chain Analysis
TABLE 39: U.S. Multimodality Diagnostic Imaging Systems Market: Detector, Magnet, Gantry, and Component Supply Analysis
TABLE 40: U.S. Multimodality Diagnostic Imaging Systems Market: Digitalization and Enterprise Imaging Impact
TABLE 41: U.S. Multimodality Diagnostic Imaging Systems Market: Application & Innovation Landscape
TABLE 42: U.S. Multimodality Diagnostic Imaging Systems Market: FDA Regulatory Framework Analysis
TABLE 43: U.S. Multimodality Diagnostic Imaging Systems Market: CMS Reimbursement and Coverage Landscape
TABLE 44: U.S. Multimodality Diagnostic Imaging Systems Market: Radiopharmaceutical Regulatory and Distribution Environment
TABLE 45: U.S. Multimodality Diagnostic Imaging Systems Market: Import, Export, and Tariff Impact
TABLE 46: U.S. Multimodality Diagnostic Imaging Systems Market: Government Initiatives and Public Health Programs
TABLE 47: U.S. Multimodality Diagnostic Imaging Systems Market: Impact of Escalating Geopolitical and Supply-Chain Tensions
TABLE 48: U.S. Multimodality Diagnostic Imaging Systems Market: Hospital Value Analysis Committee Decision Framework
TABLE 49: U.S. Multimodality Diagnostic Imaging Systems Market: Cybersecurity, HIPAA, and Imaging Data-Governance Analysis
TABLE 50: U.S. Multimodality Diagnostic Imaging Systems Market: Sustainability, Energy Consumption, and Equipment Lifecycle Analysis
TABLE 51: U.S. Multimodality Diagnostic Imaging Systems Market: System Type Snapshot, 2025
TABLE 52: Segment Dashboard; Definition and Scope, by System Type
TABLE 53: U.S. Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 54: U.S. Multimodality Diagnostic Imaging Systems Market: Segment Share Analysis, by System Type, 2025 & 2035 (%)
TABLE 55: U.S. Multimodality Diagnostic Imaging Systems Market: PET/CT Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. Multimodality Diagnostic Imaging Systems Market: SPECT/CT Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. Multimodality Diagnostic Imaging Systems Market: PET/MRI Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Multimodality Diagnostic Imaging Systems Market: Multimodality Image-Fusion and Analysis Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. Multimodality Diagnostic Imaging Systems Market: Other Integrated Hybrid Imaging Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. Multimodality Diagnostic Imaging Systems Market: Clinical Application Snapshot, 2025
TABLE 61: Segment Dashboard; Definition and Scope, by Clinical Application
TABLE 62: U.S. Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 63: U.S. Multimodality Diagnostic Imaging Systems Market: Segment Share Analysis, by Clinical Application, 2025 & 2035 (%)
TABLE 64: U.S. Multimodality Diagnostic Imaging Systems Market: Oncology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. Multimodality Diagnostic Imaging Systems Market: Neurology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. Multimodality Diagnostic Imaging Systems Market: Cardiology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. Multimodality Diagnostic Imaging Systems Market: Musculoskeletal and Orthopedic Imaging Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: U.S. Multimodality Diagnostic Imaging Systems Market: Other Clinical Applications Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: U.S. Multimodality Diagnostic Imaging Systems Market: Technology and Configuration Snapshot, 2025
TABLE 70: Segment Dashboard; Definition and Scope, by Technology and Configuration
TABLE 71: U.S. Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 72: U.S. Multimodality Diagnostic Imaging Systems Market: Segment Share Analysis, by Technology and Configuration, 2025 & 2035 (%)
TABLE 73: U.S. Multimodality Diagnostic Imaging Systems Market: Fixed Integrated Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. Multimodality Diagnostic Imaging Systems Market: Sequential and Modular Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. Multimodality Diagnostic Imaging Systems Market: Software-Based Multimodality Fusion Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. Multimodality Diagnostic Imaging Systems Market: Mobile and Relocatable Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: U.S. Multimodality Diagnostic Imaging Systems Market: AI-Enabled Quantitative Imaging Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: U.S. Multimodality Diagnostic Imaging Systems Market: End User Snapshot, 2025
TABLE 79: Segment Dashboard; Definition and Scope, by End User
TABLE 80: U.S. Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 81: U.S. Multimodality Diagnostic Imaging Systems Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 82: U.S. Multimodality Diagnostic Imaging Systems Market: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. Multimodality Diagnostic Imaging Systems Market: Freestanding Diagnostic Imaging Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: U.S. Multimodality Diagnostic Imaging Systems Market: Cancer Centers and Radiation Oncology Facilities Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: U.S. Multimodality Diagnostic Imaging Systems Market: Academic Medical Centers and Research Institutes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 86: U.S. Multimodality Diagnostic Imaging Systems Market: Ambulatory Specialty and Physician-Owned Facilities Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 87: U.S. Multimodality Diagnostic Imaging Systems Market: Procurement Channel Snapshot, 2025
TABLE 88: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 89: U.S. Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 90: U.S. Multimodality Diagnostic Imaging Systems Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 91: U.S. Multimodality Diagnostic Imaging Systems Market: Direct Hospital and Health System Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 92: U.S. Multimodality Diagnostic Imaging Systems Market: Integrated Delivery Network Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 93: U.S. Multimodality Diagnostic Imaging Systems Market: Group Purchasing Organization Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 94: U.S. Multimodality Diagnostic Imaging Systems Market: Distributor, Reseller, and Refurbished Equipment Channels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 95: U.S. Multimodality Diagnostic Imaging Systems Market: Leasing and Equipment Financing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 96: U.S. Multimodality Diagnostic Imaging Systems Market: Managed Equipment Service Agreements Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: U.S. Multimodality Diagnostic Imaging Systems Market: Mobile and Shared-Service Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: U.S. Multimodality Diagnostic Imaging Systems Market: Software Subscription and Cloud-Based Licensing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: U.S. Multimodality Diagnostic Imaging Systems Market: Regional Snapshot, 2025
TABLE 100: Segment Dashboard; Definition and Scope, by Geography
TABLE 101: U.S. Multimodality Diagnostic Imaging Systems Market, by Geography, 2021–2035 (US$ Billion)
TABLE 102: U.S. Multimodality Diagnostic Imaging Systems Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 103: U.S. Multimodality Diagnostic Imaging Systems Market: Regional Installed-Base and Equipment Replacement Analysis
TABLE 104: U.S. Multimodality Diagnostic Imaging Systems Market: Regional Imaging Procedure Volume Analysis
TABLE 105: U.S. Multimodality Diagnostic Imaging Systems Market: Regional Radiopharmaceutical Availability and Distribution Analysis
TABLE 106: U.S. Multimodality Diagnostic Imaging Systems Market: Regional Academic Medical Center and Research Ecosystem Analysis
TABLE 107: West Region U.S. Multimodality Diagnostic Imaging Systems Market: Regional Overview and Trends
TABLE 108: West Region U.S. Multimodality Diagnostic Imaging Systems Market: Imaging System Manufacturers, Distributors, and Procurement Ecosystem
TABLE 109: West Region U.S. Multimodality Diagnostic Imaging Systems Market, by State, 2021–2035 (US$ Billion)
TABLE 110: West Region U.S. Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 111: West Region U.S. Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 112: West Region U.S. Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 113: West Region U.S. Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 114: West Region U.S. Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 115: California Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 116: California Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 117: California Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 118: California Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 119: California Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 120: Washington Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 121: Washington Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 122: Washington Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 123: Washington Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 124: Washington Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 125: Arizona Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 126: Arizona Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 127: Arizona Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 128: Arizona Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 129: Arizona Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 130: Colorado Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 131: Colorado Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 132: Colorado Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 133: Colorado Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 134: Colorado Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 135: Oregon Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 136: Oregon Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 137: Oregon Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 138: Oregon Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 139: Oregon Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 140: Utah Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 141: Utah Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 142: Utah Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 143: Utah Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 144: Utah Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 145: Nevada Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 146: Nevada Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 147: Nevada Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 148: Nevada Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 149: Nevada Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 150: New Mexico Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 151: New Mexico Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 152: New Mexico Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 153: New Mexico Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 154: New Mexico Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 155: Idaho Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 156: Idaho Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 157: Idaho Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 158: Idaho Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 159: Idaho Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 160: Montana Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 161: Montana Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 162: Montana Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 163: Montana Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 164: Montana Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 165: Wyoming Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 166: Wyoming Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 167: Wyoming Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 168: Wyoming Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 169: Wyoming Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 170: Alaska Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 171: Alaska Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 172: Alaska Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 173: Alaska Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 174: Alaska Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 175: Hawaii Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 176: Hawaii Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 177: Hawaii Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 178: Hawaii Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 179: Hawaii Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 180: Northeast Region U.S. Multimodality Diagnostic Imaging Systems Market: Regional Overview and Trends
TABLE 181: Northeast Region U.S. Multimodality Diagnostic Imaging Systems Market: Imaging System Manufacturers, Distributors, and Procurement Ecosystem
TABLE 182: Northeast Region U.S. Multimodality Diagnostic Imaging Systems Market, by State, 2021–2035 (US$ Billion)
TABLE 183: Northeast Region U.S. Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 184: Northeast Region U.S. Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 185: Northeast Region U.S. Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 186: Northeast Region U.S. Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 187: Northeast Region U.S. Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 188: New York Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 189: New York Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 190: New York Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 191: New York Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 192: New York Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 193: Massachusetts Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 194: Massachusetts Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 195: Massachusetts Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 196: Massachusetts Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 197: Massachusetts Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 198: New Jersey Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 199: New Jersey Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 200: New Jersey Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 201: New Jersey Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 202: New Jersey Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 203: Pennsylvania Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 204: Pennsylvania Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 205: Pennsylvania Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 206: Pennsylvania Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 207: Pennsylvania Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 208: Connecticut Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 209: Connecticut Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 210: Connecticut Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 211: Connecticut Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 212: Connecticut Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 213: Maine Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 214: Maine Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 215: Maine Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 216: Maine Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 217: Maine Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 218: Vermont Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 219: Vermont Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 220: Vermont Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 221: Vermont Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 222: Vermont Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 223: New Hampshire Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 224: New Hampshire Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 225: New Hampshire Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 226: New Hampshire Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 227: New Hampshire Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 228: Rhode Island Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 229: Rhode Island Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 230: Rhode Island Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 231: Rhode Island Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 232: Rhode Island Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 233: South Region U.S. Multimodality Diagnostic Imaging Systems Market: Regional Overview and Trends
TABLE 234: South Region U.S. Multimodality Diagnostic Imaging Systems Market: Imaging System Manufacturers, Distributors, and Procurement Ecosystem
TABLE 235: South Region U.S. Multimodality Diagnostic Imaging Systems Market, by State, 2021–2035 (US$ Billion)
TABLE 236: South Region U.S. Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 237: South Region U.S. Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 238: South Region U.S. Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 239: South Region U.S. Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 240: South Region U.S. Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 241: Texas Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 242: Texas Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 243: Texas Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 244: Texas Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 245: Texas Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 246: Florida Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 247: Florida Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 248: Florida Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 249: Florida Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 250: Florida Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 251: Georgia Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 252: Georgia Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 253: Georgia Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 254: Georgia Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 255: Georgia Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 256: North Carolina Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 257: North Carolina Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 258: North Carolina Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 259: North Carolina Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 260: North Carolina Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 261: Tennessee Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 262: Tennessee Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 263: Tennessee Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 264: Tennessee Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 265: Tennessee Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 266: South Carolina Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 267: South Carolina Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 268: South Carolina Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 269: South Carolina Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 270: South Carolina Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 271: Alabama Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 272: Alabama Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 273: Alabama Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 274: Alabama Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 275: Alabama Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 276: Mississippi Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 277: Mississippi Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 278: Mississippi Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 279: Mississippi Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 280: Mississippi Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 281: Louisiana Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 282: Louisiana Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 283: Louisiana Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 284: Louisiana Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 285: Louisiana Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 286: Arkansas Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 287: Arkansas Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 288: Arkansas Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 289: Arkansas Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 290: Arkansas Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 291: Kentucky Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 292: Kentucky Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 293: Kentucky Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 294: Kentucky Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 295: Kentucky Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 296: Oklahoma Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 297: Oklahoma Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 298: Oklahoma Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 299: Oklahoma Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 300: Oklahoma Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 301: Virginia Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 302: Virginia Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 303: Virginia Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 304: Virginia Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 305: Virginia Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 306: Maryland Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 307: Maryland Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 308: Maryland Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 309: Maryland Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 310: Maryland Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 311: West Virginia Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 312: West Virginia Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 313: West Virginia Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 314: West Virginia Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 315: West Virginia Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 316: Delaware Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 317: Delaware Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 318: Delaware Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 319: Delaware Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 320: Delaware Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 321: District of Columbia Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 322: District of Columbia Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 323: District of Columbia Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 324: District of Columbia Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 325: District of Columbia Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 326: Midwest Region U.S. Multimodality Diagnostic Imaging Systems Market: Regional Overview and Trends
TABLE 327: Midwest Region U.S. Multimodality Diagnostic Imaging Systems Market: Imaging System Manufacturers, Distributors, and Procurement Ecosystem
TABLE 328: Midwest Region U.S. Multimodality Diagnostic Imaging Systems Market, by State, 2021–2035 (US$ Billion)
TABLE 329: Midwest Region U.S. Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 330: Midwest Region U.S. Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 331: Midwest Region U.S. Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 332: Midwest Region U.S. Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 333: Midwest Region U.S. Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 334: Illinois Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 335: Illinois Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 336: Illinois Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 337: Illinois Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 338: Illinois Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 339: Ohio Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 340: Ohio Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 341: Ohio Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 342: Ohio Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 343: Ohio Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 344: Michigan Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 345: Michigan Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 346: Michigan Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 347: Michigan Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 348: Michigan Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 349: Minnesota Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 350: Minnesota Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 351: Minnesota Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 352: Minnesota Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 353: Minnesota Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 354: Indiana Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 355: Indiana Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 356: Indiana Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 357: Indiana Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 358: Indiana Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 359: Wisconsin Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 360: Wisconsin Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 361: Wisconsin Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 362: Wisconsin Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 363: Wisconsin Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 364: Missouri Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 365: Missouri Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 366: Missouri Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 367: Missouri Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 368: Missouri Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 369: Iowa Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 370: Iowa Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 371: Iowa Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 372: Iowa Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 373: Iowa Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 374: Kansas Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 375: Kansas Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 376: Kansas Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 377: Kansas Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 378: Kansas Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 379: Nebraska Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 380: Nebraska Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 381: Nebraska Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 382: Nebraska Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 383: Nebraska Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 384: North Dakota Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 385: North Dakota Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 386: North Dakota Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 387: North Dakota Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 388: North Dakota Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 389: South Dakota Multimodality Diagnostic Imaging Systems Market, by System Type, 2021–2035 (US$ Billion)
TABLE 390: South Dakota Multimodality Diagnostic Imaging Systems Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 391: South Dakota Multimodality Diagnostic Imaging Systems Market, by Technology and Configuration, 2021–2035 (US$ Billion)
TABLE 392: South Dakota Multimodality Diagnostic Imaging Systems Market, by End User, 2021–2035 (US$ Billion)
TABLE 393: South Dakota Multimodality Diagnostic Imaging Systems Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 394: U.S. Multimodality Diagnostic Imaging Systems Market: Competitive Landscape Snapshot, 2025
TABLE 395: U.S. Multimodality Diagnostic Imaging Systems Market: Key Company Market Share Analysis, 2025
TABLE 396: U.S. Multimodality Diagnostic Imaging Systems Market: Market Concentration and Competitive Intensity Analysis
TABLE 397: U.S. Multimodality Diagnostic Imaging Systems Market: Company Positioning Matrix
TABLE 398: U.S. Multimodality Diagnostic Imaging Systems Market: Product Portfolio Benchmarking of Key Players
TABLE 399: U.S. Multimodality Diagnostic Imaging Systems Market: Technology and Detector Capability Benchmarking
TABLE 400: U.S. Multimodality Diagnostic Imaging Systems Market: AI, Software, and Enterprise Imaging Benchmarking
TABLE 401: U.S. Multimodality Diagnostic Imaging Systems Market: Service Network and Installed-Base Benchmarking
TABLE 402: U.S. Multimodality Diagnostic Imaging Systems Market: Strategic Developments, Partnerships, M&A, and Product Launches
TABLE 403: GE HealthCare: Company Profile
TABLE 404: Siemens Healthineers: Company Profile
TABLE 405: Philips: Company Profile
TABLE 406: Canon Medical Systems USA: Company Profile
TABLE 407: United Imaging Healthcare: Company Profile
TABLE 408: Fujifilm Healthcare Americas: Company Profile
TABLE 409: Shimadzu Medical Systems USA: Company Profile
TABLE 410: Samsung NeuroLogica: Company Profile
TABLE 411: Mediso USA: Company Profile
TABLE 412: Spectrum Dynamics Medical: Company Profile
TABLE 413: Esaote North America: Company Profile
TABLE 414: Bruker Corporation: Company Profile
TABLE 415: Cubresa: Company Profile
TABLE 416: Positron Corporation: Company Profile
TABLE 417: MiE America: Company Profile
TABLE 418: Digirad Health: Company Profile
TABLE 419: MIM Software: Company Profile
TABLE 420: Mirada Medical: Company Profile
TABLE 421: Hermes Medical Solutions: Company Profile
TABLE 422: Sectra: Company Profile
TABLE 423: Intelerad: Company Profile
TABLE 424: Visage Imaging: Company Profile
TABLE 425: TeraRecon: Company Profile
TABLE 426: Agfa HealthCare: Company Profile
TABLE 427: Carestream Health: Company Profile
TABLE 428: U.S. Multimodality Diagnostic Imaging Systems Market: Future Market Scenario Analysis, 2026–2035
TABLE 429: U.S. Multimodality Diagnostic Imaging Systems Market: Optimistic Scenario, 2026–2035
TABLE 430: U.S. Multimodality Diagnostic Imaging Systems Market: Realistic Scenario, 2026–2035
TABLE 431: U.S. Multimodality Diagnostic Imaging Systems Market: Pessimistic Scenario, 2026–2035
TABLE 432: U.S. Multimodality Diagnostic Imaging Systems Market: Digital PET Detector Technology Impact
TABLE 433: U.S. Multimodality Diagnostic Imaging Systems Market: Total-Body and Long-Axial-Field-of-View PET/CT Impact
TABLE 434: U.S. Multimodality Diagnostic Imaging Systems Market: Quantitative SPECT/CT Impact
TABLE 435: U.S. Multimodality Diagnostic Imaging Systems Market: Advanced PET/MRI Impact
TABLE 436: U.S. Multimodality Diagnostic Imaging Systems Market: Photon-Counting and Spectral CT Integration Impact
TABLE 437: U.S. Multimodality Diagnostic Imaging Systems Market: AI-Assisted Reconstruction and Multimodality Fusion Impact
TABLE 438: U.S. Multimodality Diagnostic Imaging Systems Market: Theranostics Dosimetry and Molecular Imaging Platform Impact
TABLE 439: U.S. Multimodality Diagnostic Imaging Systems Market: Cloud-Based Enterprise Imaging Impact
TABLE 440: U.S. Multimodality Diagnostic Imaging Systems Market: Emerging Business Trends
TABLE 441: U.S. Multimodality Diagnostic Imaging Systems Market: Imaging-as-a-Service and Managed Equipment Service Models
TABLE 442: U.S. Multimodality Diagnostic Imaging Systems Market: Business Opportunities for Startups and Existing Players
TABLE 443: U.S. Multimodality Diagnostic Imaging Systems Market: Investment Prioritization Matrix
TABLE 444: U.S. Multimodality Diagnostic Imaging Systems Market: Technology Adoption Roadmap, 2026–2035
TABLE 445: U.S. Multimodality Diagnostic Imaging Systems Market: Future Hospital Procurement and Replacement Outlook
TABLE 446: U.S. Multimodality Diagnostic Imaging Systems Market: Strategic Recommendations for Imaging System Manufacturers
TABLE 447: U.S. Multimodality Diagnostic Imaging Systems Market: Strategic Recommendations for Software and AI Platform Developers
TABLE 448: U.S. Multimodality Diagnostic Imaging Systems Market: Strategic Recommendations for Hospitals and Integrated Health Systems
TABLE 449: U.S. Multimodality Diagnostic Imaging Systems Market: Strategic Recommendations for Diagnostic Imaging Center Operators
TABLE 450: U.S. Multimodality Diagnostic Imaging Systems Market: Strategic Recommendations for Cancer Centers and Theranostics Providers
TABLE 451: U.S. Multimodality Diagnostic Imaging Systems Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 452: U.S. Multimodality Diagnostic Imaging Systems Market: Strategic Recommendations for Distributors, Resellers, and Channel Partners
TABLE 453: U.S. Multimodality Diagnostic Imaging Systems Market: Strategic Recommendations for New Entrants and Startups
TABLE 454: U.S. Multimodality Diagnostic Imaging Systems Market: Go-to-Market Strategy Considerations
TABLE 455: U.S. Multimodality Diagnostic Imaging Systems Market: Product Positioning and Portfolio Expansion Guidance
TABLE 456: U.S. Multimodality Diagnostic Imaging Systems Market: Hospital Value-Proposition Development
TABLE 457: U.S. Multimodality Diagnostic Imaging Systems Market: Geographic Expansion and State Prioritization Strategy
TABLE 458: U.S. Multimodality Diagnostic Imaging Systems Market: Partnership, Acquisition, and Clinical Collaboration Strategy
TABLE 459: U.S. Multimodality Diagnostic Imaging Systems Market: Pricing, Financing, and Managed-Service Strategy
TABLE 460: U.S. Multimodality Diagnostic Imaging Systems Market: Scope Limitation
TABLE 461: U.S. Multimodality Diagnostic Imaging Systems Market: Market Definition and Inclusion Limitation
TABLE 462: U.S. Multimodality Diagnostic Imaging Systems Market: Data Use Limitation
TABLE 463: U.S. Multimodality Diagnostic Imaging Systems Market: Forecasting Limitation
TABLE 464: U.S. Multimodality Diagnostic Imaging Systems Market: Legal Disclaimer
TABLE 465: U.S. Multimodality Diagnostic Imaging Systems Market: Third-Party Data Disclaimer
TABLE 466: U.S. Multimodality Diagnostic Imaging Systems Market: Company and Product Information Disclaimer
TABLE 467: U.S. Multimodality Diagnostic Imaging Systems Market: Regulatory and Reimbursement Disclaimer

List of Figures

FIGURE 1: U.S. Multimodality Diagnostic Imaging Systems Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Primary and Secondary Research Framework
FIGURE 4: Market Ecosystem Overview
FIGURE 5: Stakeholder Analysis
FIGURE 6: Executive Summary Market Snapshot, 2025
FIGURE 7: Market Attractiveness Analysis
FIGURE 8: Historical Market Size and Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 9: Forecast Market Size and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 10: Year-wise Market Growth Curve, 2021–2035
FIGURE 11: Market Drivers Impact Framework
FIGURE 12: Market Restraints Impact Framework
FIGURE 13: Market Opportunities Impact Framework
FIGURE 14: Market Challenges Impact Framework
FIGURE 15: Innovation & Patent Landscape, 2021–2025
FIGURE 16: Clinical Workflow Economics Framework
FIGURE 17: Imaging Department Productivity and Throughput Framework
FIGURE 18: Hospital Capital Procurement Decision Framework
FIGURE 19: Equipment Replacement Cycle and Installed-Base Framework
FIGURE 20: Total Cost of Ownership Framework
FIGURE 21: Radiopharmaceutical Supply and Imaging Capacity Framework
FIGURE 22: PESTEL Analysis
FIGURE 23: Porter’s Five Forces Analysis
FIGURE 24: Regional Pricing Trend Analysis, 2025–2035
FIGURE 25: Value Chain Analysis
FIGURE 26: Supply Chain Analysis
FIGURE 27: Detector, Magnet, Gantry, and Component Ecosystem
FIGURE 28: Digitalization and Enterprise Imaging Impact
FIGURE 29: Application & Innovation Landscape
FIGURE 30: FDA Regulatory Pathway Framework
FIGURE 31: CMS Reimbursement and Coverage Framework
FIGURE 32: Cybersecurity and Imaging Data-Governance Framework
FIGURE 33: Sustainability and Imaging Equipment Lifecycle Framework
FIGURE 34: System Type Segment Market Share Analysis, 2025 & 2035
FIGURE 35: System Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: PET/CT Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: SPECT/CT Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: PET/MRI Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Multimodality Image-Fusion and Analysis Platforms Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Other Integrated Hybrid Imaging Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Clinical Application Segment Market Share Analysis, 2025 & 2035
FIGURE 42: Clinical Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Oncology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Neurology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Cardiology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Musculoskeletal and Orthopedic Imaging Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Other Clinical Applications Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Technology and Configuration Segment Market Share Analysis, 2025 & 2035
FIGURE 49: Technology and Configuration Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Fixed Integrated Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Sequential and Modular Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Software-Based Multimodality Fusion Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Mobile and Relocatable Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: AI-Enabled Quantitative Imaging Platforms Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 56: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Freestanding Diagnostic Imaging Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Cancer Centers and Radiation Oncology Facilities Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Academic Medical Centers and Research Institutes Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Ambulatory Specialty and Physician-Owned Facilities Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 63: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Direct Hospital and Health System Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Integrated Delivery Network Enterprise Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Group Purchasing Organization Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Distributor, Reseller, and Refurbished Equipment Channels Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Leasing and Equipment Financing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Managed Equipment Service Agreements Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Mobile and Shared-Service Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Software Subscription and Cloud-Based Licensing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 73: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Regional Installed-Base and Equipment Replacement Analysis
FIGURE 75: Regional Radiopharmaceutical Availability and Distribution Map
FIGURE 76: West Region U.S. Multimodality Diagnostic Imaging Systems Market Share and Leading Players, 2025
FIGURE 77: West Region Market Share Analysis by State, 2025
FIGURE 78: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: California Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Washington Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Arizona Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Colorado Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Oregon Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Utah Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Nevada Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: New Mexico Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Idaho Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Montana Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Wyoming Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Alaska Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Hawaii Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Northeast Region U.S. Multimodality Diagnostic Imaging Systems Market Share and Leading Players, 2025
FIGURE 93: Northeast Region Market Share Analysis by State, 2025
FIGURE 94: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: New York Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Massachusetts Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: New Jersey Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Pennsylvania Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Connecticut Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Maine Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Vermont Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: New Hampshire Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Rhode Island Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: South Region U.S. Multimodality Diagnostic Imaging Systems Market Share and Leading Players, 2025
FIGURE 105: South Region Market Share Analysis by State, 2025
FIGURE 106: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Texas Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Florida Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Georgia Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: North Carolina Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Tennessee Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: South Carolina Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Alabama Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Mississippi Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Louisiana Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Arkansas Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: Kentucky Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: Oklahoma Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: Virginia Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 120: Maryland Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 121: West Virginia Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 122: Delaware Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 123: District of Columbia Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 124: Midwest Region U.S. Multimodality Diagnostic Imaging Systems Market Share and Leading Players, 2025
FIGURE 125: Midwest Region Market Share Analysis by State, 2025
FIGURE 126: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 127: Illinois Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 128: Ohio Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 129: Michigan Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 130: Minnesota Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 131: Indiana Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 132: Wisconsin Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 133: Missouri Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 134: Iowa Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 135: Kansas Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 136: Nebraska Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 137: North Dakota Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 138: South Dakota Multimodality Diagnostic Imaging Systems Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 139: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 140: Market Concentration and Competitive Intensity Matrix
FIGURE 141: Company Positioning Matrix
FIGURE 142: Key Player Product Portfolio Benchmarking
FIGURE 143: Technology and Detector Capability Benchmarking
FIGURE 144: AI, Software, and Enterprise Imaging Benchmarking
FIGURE 145: Service Network and Installed-Base Benchmarking
FIGURE 146: Strategic Developments, Partnerships, M&A, and Product Launches
FIGURE 147: Multimodality Diagnostic Imaging Innovation Roadmap
FIGURE 148: Digital PET and Total-Body PET/CT Adoption Roadmap
FIGURE 149: Quantitative SPECT/CT and Theranostics Opportunity Map
FIGURE 150: PET/MRI Clinical Adoption Roadmap
FIGURE 151: AI-Assisted Fusion and Quantitative Imaging Roadmap
FIGURE 152: Future Market Scenario Analysis, 2026–2035
FIGURE 153: Disruptive Technologies Impact Matrix
FIGURE 154: Emerging Business Trends Matrix
FIGURE 155: Imaging-as-a-Service and Managed Equipment Service Model
FIGURE 156: Investment Prioritization Matrix
FIGURE 157: Technology Adoption Roadmap, 2026–2035
FIGURE 158: Future Hospital Procurement and Replacement Outlook
FIGURE 159: Strategic Growth Roadmap for Imaging System Manufacturers
FIGURE 160: Go-to-Market Strategy Framework
FIGURE 161: Product Positioning and Portfolio Expansion Framework
FIGURE 162: Geographic Expansion and State Prioritization Framework
FIGURE 163: Pricing, Financing, and Managed-Service Strategy Framework
FIGURE 164: Report Scope and Disclaimer Framework